Charles joined SV in 2018 and is a Principal in the biotech team. He helps form and fund companies developing transformational new medicines, with a broad focus from new company creation to later stage public and private opportunities.
Charles’ investments, a number of which are examples of SV’s company creation approach to biotech investing, include a range of drug discovery and development companies focused on different clinical areas in companies in the UK and US. Most recently, he led SV’s investment to create and launch Draig Therapeutics which has now raised $140m. Charles also serves as a Board Director at Imbria Pharmaceuticals, and Mestag Therapeutics, which he also helped incubate and launch. He is also Board Observer at Autifony Therapeutics, EnaraBio, and Pulmocide.
Prior to joining SV, Charles qualified as an ACA after three years at Deloitte, with a focus on Life Sciences clients including SV portfolio companies and has an academic background in human genetics & molecular biology (UCL).
